UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035567
Receipt number R000040522
Scientific Title An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIL
Date of disclosure of the study information 2019/01/16
Last modified on 2024/01/22 08:49:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab
in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIL

Acronym

An exploratory study to evaluate biomarkers of J-TAIL

Scientific Title

An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab
in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIL

Scientific Title:Acronym

An exploratory study to evaluate biomarkers of J-TAIL

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To explore biomarkers in blood to select appropriate patients with locally advanced or metastatic non-small cell lung cancer for atezolizumab

Basic objectives2

Others

Basic objectives -Others

Biomarker Research

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To evaluate the correlation of values of protein expressions, concentrations of atezolizumab and molecular and functional profiling of T-cell differentiation in peripheral blood with efficacy and safety

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients enrolled in J-TAIL study and singed informed consent

Key exclusion criteria

NONE

Target sample size

250


Research contact person

Name of lead principal investigator

1st name 1. Tetsuya, 2. Akihiko, 3. Ichiro, 4. Makoto
Middle name
Last name 1. MITSUDOMI 2. GEMMA 3. YOSHINO 4. NISHIO

Organization

1. Kindai University
2. Nippon medical school
3. Chiba University
4. The Cancer Institute Hospital

Division name

1. Division of Thoracic Surgery 2. Department of pulmonary medicine and oncology 3. Department of General Thoracic Surgery 4. Department of Thoracic Medical Oncology

Zip code

1.589-8511, 2.113-8602, 3.260-8677, 4.135-8550

Address

1. 377-2 Ohno-Higashi, Osaka-Sayama, Japan 2. 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan 3. 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan 4. 3-8-31 Ariake, Koto-ku, Tokyo, Japan

TEL

0723660221.0338222131.0432227171.0335200111

Email

1.mitsudom@med.kindai.ac.jp


Public contact

Name of contact person

1st name Hayato
Middle name
Last name Konishi

Organization

MEBIX INC.

Division name

CLINICAL OPERATIONS

Zip code

105-0001

Address

3-8-21 Toranomon, Minatoku, Tokyo, Japan

TEL

03-4362-4504

Homepage URL


Email

j-tail@mebix.co.jp


Sponsor or person

Institute

Medical Affairs,
CHUGAI PHARMACEUTICAL CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

CHUGAI PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

The Japan Lung Cancer Society

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Non-Profit Organization MINS Institutional Review Board

Address

1-15-14, Dogenzaka, Shibuya, Tokyo, Japan

Tel

0364161868

Email

Npo-mins@j-irb.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 01 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2018 Year 10 Month 10 Day

Date of IRB

2018 Year 09 Month 20 Day

Anticipated trial start date

2019 Year 04 Month 10 Day

Last follow-up date

2021 Year 04 Month 16 Day

Date of closure to data entry

2021 Year 07 Month 07 Day

Date trial data considered complete

2021 Year 07 Month 31 Day

Date analysis concluded



Other

Other related information

Efficacy, Safety


Management information

Registered date

2019 Year 01 Month 16 Day

Last modified on

2024 Year 01 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040522


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name